BECTON DICKINSON & CO (BDX)

Current Report Filed: 2026-05-12

Key Insights

BD is issuing €600 million in new 3.855% Notes due 2033 to refinance maturing 1.208% Euro Notes due June 4, 2026, resulting in a 265 basis point increase in borrowing costs that will negatively impact future interest expenses.
The refinancing demonstrates BD's need to address near-term debt maturity (June 2026) and suggests the company prefers extending debt duration rather than using cash reserves, indicating potential liquidity management considerations.
Strong underwriting syndicate (Barclays, BNP Paribas, Goldman Sachs, Morgan Stanley) and expected closing by May 20, 2026 suggest market confidence in BD's creditworthiness, though the higher coupon rate reflects current market conditions and potential credit spread pressures.

Insider Trading Filed: 2026-05-08

Key Insights

Director Robert Luther Huffines acquired 210 rights to common stock under BD's Deferred Compensation Plan on 05/08/2026, with these securities converting on a one-for-one basis to common stock, bringing his total derivative holdings to 404 shares.
The acquisition includes 210 shares from dividend reinvestment since the last report, indicating ongoing dividend payments and the director's choice to reinvest distributions into company equity.
The filing references adjustments related to the combination of Biosciences and Diagnostic Solutions businesses with Waters Corp., which affected the valuation and number of previously reported derivative securities held by the reporting person.

Insider Trading Filed: 2026-05-08

Key Insights

Director Carrie L Byington acquired 105 rights to common stock through the BD Deferred Compensation Plan on 05/08/2026, bringing her total beneficial ownership to 3,699 derivative securities, indicating continued engagement with the company.
The filing references a significant corporate restructuring where BD's Biosciences and Diagnostic Solutions businesses were combined with Waters Corp., which resulted in adjustments to previously reported derivative securities held by the reporting person.
The acquisition was made through dividend reinvestment under a deferred compensation plan rather than open market purchase, suggesting passive wealth accumulation rather than active confidence signal in the stock.

Insider Trading Filed: 2026-05-08

Key Insights

CFO Roque Vitor acquired 1,721 restricted stock units (RSUs) on 05/07/2026 with $0 price, indicating a vesting or grant event rather than an open market purchase, bringing his total beneficial ownership to 8,231 shares.
The RSU grant to the CFO under the 2004 Employee and Director Equity-Based Compensation Plan represents routine executive compensation rather than a discretionary insider buy signal, suggesting confidence in company direction but not necessarily bullish market timing.
No derivative securities transactions or dispositions were reported, indicating the executive is maintaining his equity position without hedging or liquidating shares, which could be interpreted as baseline confidence in the company.

Quarterly Report Filed: 2026-05-07

Key Insights

The filing indicates a significant corporate restructuring with the Waters Corporation separation (SpinOff entity references dated 2026-02-09), which represents a major portfolio change for BDX and requires investors to reassess the remaining company's strategic direction and growth profile.
Multiple debt instruments are referenced with near-term maturities (Notes due June 2026, December 2026), suggesting BDX is managing refinancing activities during this period and investors should monitor debt refinancing terms and interest rate impacts.
Active share repurchase programs are documented (Accelerated Share Repurchase Program in Q2 2026 and open market repurchases in Q1 2026), indicating management confidence in valuation while the company undergoes significant structural changes.
The filing structure shows discontinued operations being disposed through spin-off mechanisms rather than traditional sale, which has different tax and accounting implications that could affect net proceeds and shareholder value realization.

Current Report Filed: 2026-05-07

Key Insights

BD announced Q2 fiscal 2026 financial results (quarter ending March 31, 2026) on May 7, 2026, with the press release containing non-GAAP adjusted measures indicating management's focus on operational performance metrics.
The company has multiple near-term debt maturities including notes due June 4, 2026 (1.208%) and December 15, 2026 (1.900%), suggesting active debt management and refinancing activities in the near term.
This is a routine earnings announcement filing with no disclosure of material agreements, leadership changes, or significant operational disruptions, indicating normal business operations.

Current Report Filed: 2026-04-29

Key Insights

BDX approved amendments to its bylaws on April 28, 2026, primarily updating the advance notice provision for contested elections, indicating routine corporate governance housekeeping rather than any material business changes.
The filing contains no material business developments, earnings announcements, executive changes, or strategic initiatives—this is a standard governance-focused 8-K with limited investor impact.
Multiple debt securities are listed as registered, with some notes due in mid-2026 (June and December), suggesting the company is managing near-term debt obligations during this filing period.

Insider Trading Filed: 2026-04-28

Key Insights

Michael Feld, EVP and Chief Revenue Officer, sold 74 shares of BDX at $151.94 per share on April 27, 2026, reducing his direct holdings to 21,159 shares—a modest transaction representing less than 0.4% of his position.
The sale was executed under a Rule 10b5-1 trading plan adopted on February 7, 2025, indicating this was a pre-planned, systematic transaction rather than a discretionary decision, which reduces concerns about negative insider sentiment.
As an executive officer responsible for revenue generation, Feld's minimal insider selling activity suggests confidence in the company's growth trajectory and does not indicate material concerns about BDX's business prospects.

Current Report Filed: 2026-04-09

Key Insights

Becton, Dickinson and Company (BD) announced the retirement of Richard E. Byrd, Executive Vice President and President of the Interventional segment, effective in June 2026.
BD intends to name a successor to Mr. Byrd prior to his retirement date, indicating a smooth transition of leadership in the Interventional segment.
The company issued a press release related to Mr. Byrd's retirement, providing transparency to investors on this key organizational change.

Insider Trading Filed: 2026-04-06

Key Insights

Shana Carol Neal, the EVP and Chief People Officer, has disposed of 1,146 shares of Becton Dickinson & Co (BDX) common stock through a stock withholding transaction to cover tax obligations.
The reported transaction reflects adjustments made to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person, in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
This insider transaction provides insight into the executive's equity holdings and portfolio management, but does not necessarily signal a broader market sentiment or outlook for the company.

Current Report Filed: 2026-04-02

Key Insights

Becton, Dickinson and Company (BD) has completed the spin-off of its Biosciences and Diagnostic Solutions business and combination with Waters Corporation, which will allow the company to focus on its core operations.
BD has provided recast historical financial information to assist investors in understanding the company's standalone operating results from continuing operations, excluding the spun-off business.
The company has disclosed several debt instruments, including notes due in 2026, 2031, 2032, and 2036, which could impact its capital structure and financing costs going forward.

Insider Trading Filed: 2026-03-27

Key Insights

The reporting person, Michael Feld, who is the Executive Vice President and Chief Revenue Officer of Becton Dickinson & Co, sold 75 shares of the company's common stock on March 26, 2026 at a price of $156.83 per share.
This transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025, indicating a pre-planned insider sale.
The reporting person still holds 21,233 shares of Becton Dickinson & Co's common stock directly, suggesting he maintains a significant equity position in the company.

Insider Trading Filed: 2026-03-17

Key Insights

Lanesha Minnix, the Executive Vice President and General Counsel of Becton Dickinson & Co (BDX), has acquired 7,492 shares of the company's common stock, indicating insider buying activity.
The acquisition of shares was made through a direct award of restricted stock units under the company's 2004 Employee and Director Equity-Based Compensation Plan, suggesting the compensation structure aligns executive interests with shareholders.
Insider buying can be seen as a positive signal, as executives often have an information advantage and may be optimistic about the company's future prospects.

Current Report Filed: 2026-02-25

Key Insights

Becton, Dickinson and Company announced the early tender results and pricing for its previously announced tender offers to purchase up to $2 billion in aggregate principal amount of various outstanding notes.
The company exercised its right to increase the offer subcap for the 4.685% Senior Notes and the aggregate offer cap, indicating potential demand for the tender offers.
Holders of the notes had to tender by the early tender date in order to receive the early tender payment, with the 3.794% Senior Notes being accepted on a prorated basis due to the aggregate offer cap being exceeded.

Insider Trading Filed: 2026-02-18

Key Insights

Insider Bertram L. Scott sold 953 shares of Becton Dickinson & Co (BDX) stock on February 18, 2026 at $182.61 per share, reducing his direct ownership to 36,763 shares.
This insider sale, while not a large percentage of his total holdings, could signal that he sees limited upside in the stock in the near-term.
Investors should monitor any further insider selling activity at Becton Dickinson & Co to gauge sentiment and potential concerns about the company's performance or outlook.

Insider Trading Filed: 2026-02-11

Key Insights

Becton Dickinson & Co. distributed all of its shares of Augusta SpinCo Corp. to its public stockholders on a pro rata basis, effectively spinning off the subsidiary.
This transaction was done pursuant to a Separation Agreement between Becton Dickinson, Augusta SpinCo, and Waters Corporation, suggesting a strategic move to streamline the company's business operations.
The reporting of this Form 4 filing indicates insider changes, but the nature of the transaction (a spinoff) suggests it is more of a structural reorganization rather than a significant change in ownership or control.

Current Report Filed: 2026-02-10

Key Insights

Becton Dickinson announced a tender offer to purchase up to $1.6 billion of its outstanding senior notes and debentures, indicating active balance sheet management.
The company is targeting a diverse set of fixed-income securities across different maturity dates, suggesting a strategic approach to liability optimization.
The tender offer covers 15 different note and debenture series, providing Becton Dickinson flexibility to manage its debt profile and potentially improve its capital structure.

Current Report Filed: 2026-02-09

Key Insights

Becton Dickinson is completing the spin-off of its Biosciences and Diagnostic Solutions business and combining it with Waters Corporation through a merger transaction.
The company has entered into several key agreements to govern the separation, including a Tax Matters Agreement, an Employee Matters Agreement, and an Intellectual Property Matters Agreement.
The spin-off and merger will allow Becton Dickinson to focus on its core medical device and pharmaceutical businesses, potentially unlocking value for shareholders.

Current Report Filed: 2026-02-09

Key Insights

Becton Dickinson reported its Q1 2026 financial results, which include non-GAAP financial measures that should be reviewed for additional context.
The company did not indicate it is an emerging growth company, suggesting it is a more mature, established organization.
Becton Dickinson has several debt securities trading on the New York Stock Exchange, including notes with maturity dates ranging from 2026 to 2036.

Quarterly Report Filed: 2026-02-09

Key Insights

The company has announced the divestiture of its Waters Corporation subsidiary, which could impact the company's future financial performance.
Becton Dickinson has been involved in several legal proceedings, including claims related to hernia products and implantable port products, which could result in financial liabilities.
The company has made several debt issuances, including notes due in 2026, 2031, and 2032, which may impact its capital structure and financial flexibility.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information